Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Extended Group Written Exposure Therapy for Comorbid PTSD and BPD (Traits)

4. maj 2026 opdateret af: Jennifer Ip, St. Joseph's Healthcare Hamilton

The goal of this open label trial is to evaluate the effectiveness of virtual group extended Written Exposure Therapy (GE-WET) in reducing Post-Traumatic Stress Disorder (PTSD) symptoms in patients with comorbid PTSD and Borderline Personality Disorder (BPD) or BPD traits. GE-WET involves attending weekly 2-hour group WET sessions for the duration of 10 weeks, in which they write about their trauma experience using specific instructions.

This study will be conducted at St. Joseph's Healthcare Hamilton's Community Psychiatry Clinic with clients wait listed for PTSD treatment (ages 18- 65, any gender, co-morbid PTSD and BPD/BPD traits).

The main questions this study aims to answer are:

Does GE-WET reduce PTSD symptoms (based on PCL-5 measures) in this population (outpatient clients ages 18-65 of any gender, with a diagnosis of PTSD and BPD or BPD traits)?

Does GE-WET result in reduced drop-out rates for this population, compared to that of other evidence-based treatment for PTSD?

What are participants subjective experience of GE-WET?

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

63

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Canada
    • Ontario
      • Hamilton, Ontario, Canada
        • St. Joseph's Healthcare Hamilton

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  • Reading and writing proficiency in English
  • Access to an electronic device to attend virtual group meetings
  • Age 18-65
  • Previous diagnosis of Posttraumatic Stress Disorder (PTSD) and Borderline Personality Disorder (BPD)/BPD traits
  • Completion of a DBT skills group via St. Joe's Community Psychiatry Clinic

Exclusion Criteria:

  • Diagnosis of an active severe substance use disorder or psychotic disorder
  • Untreated active psychotic symptoms, mania, or hypomania
  • Has attempted suicide in the 2 months prior to treatment beginning
  • Has engaged in high-risk self-harm (e.g., cutting, burning, asphyxiation) in the 2 months prior to beginning treatment
  • Has completed Cognitive Processing Therapy or another active PTSD treatment (i.e., prolonged exposure) in the past year

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Group Extended Written Exposure Therapy
Participants will be invited to participate in group extended Written Exposure Therapy (described in the Interventions section).
Adfærdsmæssigt: Group Written Exposure Therapy
Group Extended Written Exposure Therapy (GE-WET) is a time-limited cognitive behavioural therapy for Posttraumatic Stress Disorder (PTSD) aimed at allowing patients to process their traumatic experiences in a safe environment. GE-WET will consist of 10 weekly group sessions. Participants will be asked to complete weekly in-session written exposures where they will recount their traumatic experience. The written exposure will be followed by a guided discussion about the experience of writing the exposure. There is no homework assigned between sessions. However, group members will be asked to refrain from avoiding thinking about the trauma between sessions.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Tidsramme
PTSD Checklist for DSM-5 (PCL-5)
Tidsramme: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Posttraumatic Cognitions Inventory
Tidsramme: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
A 36-item self-report questionnaire that assesses negative thoughts across three subscales: negative cognitions about the self (e.g., "I am a weak person"), negative cognitions about the world (e.g., "I have to be on guard all the time"), and self-blame (e.g., "the event happened because of the way I acted"). The PTCI has demonstrated good internal consistency, test-retest reliability, and convergent validity with other measures of posttraumatic cognitions.
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
Borderline Symptom List- Short Version (BSL-23)
Tidsramme: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
The BSL-23 is a 23-item self-report measure that assesses for DSM borderline personality disorder symptomatology as well as associated problems such as self-criticism, loneliness, helplessness, and problems with trust. The BSL-23 has demonstrated high internal consistency and test-retest reliability, and strong convergent validity with correlations with depression and general psychopathology severity.
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
Borderline Symptom List Behaviour Supplement
Tidsramme: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
The BSL-23 Behaviour Supplement is an 11-item supplemental measure used to assess frequency of problematic behaviours (e.g., non-suicidal self-injury, suicide attempts, suicidal communication, angry outbursts, misuse of substances, etc.) associated with borderline personality disorder.
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
Toronto Alexithymia Scale-20 (TAS-20)
Tidsramme: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
The TAS-20 is a 20-item self-report measure assessing for alexithymia (i.e., issues in identifying and processing emotions) across three factors: difficulty identifying feelings, difficulty describing feelings, and externally-oriented thinking. The TAS-20 has demonstrated adequate levels of convergent validity, good internal consistency, and good test-retest reliability.
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
Experience of Shame Scale (ESS)
Tidsramme: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
The ESS is a 25-item self-report measure assessing characterological shame (e.g., shame of personal habits or personal ability), behavioural shame (e.g., shame in doing or saying something wrong), and bodily shame (e.g., shame regarding one's body). The ESS has demonstrated good internal consistency and test-retest reliability.
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
Difficulties in Emotion Regulation Scale (DERS)
Tidsramme: From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
The DERS is a widely used 36-item self-report measure assessing six dimensions of emotion regulation difficulties. The DERS demonstrates good internal consistency, convergent validity, and predictive validity of behaviours reflective of emotion regulation difficulties.
From pre-treatment (1 week before the start of group) to one-month follow-up at about 4 months
Group Cohesion Scale - Revised (GCS-R)
Tidsramme: Mid treatment (at about 5 weeks after start of group) and post treatment (at about 10 weeks)
The GCS-R is a self-report measure that measure's group member's perception of their group and the strength of the bonds formed. The GCS-R showed high reliability for use in research and is sensitive to detecting changes in cohesiveness as a function of group development.
Mid treatment (at about 5 weeks after start of group) and post treatment (at about 10 weeks)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

St. Joseph's Healthcare Hamilton

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. juni 2026

Primær færdiggørelse (Anslået)

1. juni 2028

Studieafslutning (Anslået)

1. december 2028

Datoer for studieregistrering

Først indsendt

20. april 2026

Først indsendt, der opfyldte QC-kriterier

4. maj 2026

Først opslået (Faktiske)

8. maj 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

8. maj 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

4. maj 2026

Sidst verificeret

1. maj 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • 18906

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Group Written Exposure Therapy

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Rwanda

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner